LGND
Ligand Pharmaceuticals Incorporated
NASDAQ · Healthcare · Biotechnology · US
$285.60
−1.43%Aug 6, 2026, 00:00 UTC
Ligand Pharmaceuticals reported Q2 2026 financial results with total revenues of $63.7 million, net income of $48.5 million, and diluted EPS of $2.22.
Aug 6, 2026, 00:00 UTC
Ligand Pharmaceuticals issued convertible debt with an aggregate principal amount of $700 million.
Source:Jul 14, 2026, 13:00 UTC
Ligand Pharmaceuticals completed its acquisition of XOMA Royalty Corporation.
Jun 22, 2026, 00:00 UTC
Ligand Pharmaceuticals entered into a Consent and Fourth Amendment to its Credit Agreement, consenting to its convertible note offering and updating minimum Consolidated EBITDA covenants.